At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 131 enrolled
Drug / intervention
Everolimus +1 moredrug
Likely dose
Everolimus 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
In Brief
A Phase 2 clinical trial evaluating Everolimus and Sunitinib for Advanced Non-clear Cell Renal Cell Carcinoma. Completed, enrolled 131 participants across 18 sites in 3 countries.
Detailed Summary
To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United Kingdom, United States
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartSep 2010
Primary CompletionFeb 2015
Study CompletionApr 2015
TodayJul 2026
First PostedApr 22, 2010
Enrollment StartSep 1, 2010
Primary CompletionFeb 1, 2015
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 16.2 years ago
Interventions
Everolimusdrug
Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
Sunitinibdrug
50 mg daily by mouth on days 1 through 28 of each 42 day cycle.